Evaluation of Novel Iron-based Lymphatic Mapping Agent, Magtrace, for Delayed Sentinel Lymph Node Biopsy (SLNB) in Ductal Carcinoma In-Situ (DCIS)

Name: Evaluation of Novel Iron-based Lymphatic Mapping Agent, Magtrace, for Delayed Sentinel Lymph Node Biopsy (SLNB) in Ductal Carcinoma In-Situ (DCIS)
Published: 2026
License: Public Domain

University of Florida · 2026

ClinicalTrials.gov · Datasets · License: Public Domain · 2026

Open Source ↗

breast

ductal carcinoma in situ, superparamagnetic oxide (spio/magtrace), sentinel lymph node biopsy, mastectomy, breast, lymphedema, interventional, phase2

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Evaluation of Novel Iron-based Lymphatic Mapping Agent, Magtrace, for Delayed Sentinel Lymph Node Biopsy (SLNB) in Ductal Carcinoma In-Situ (DCIS)

Related documents